Genestra TFE Female Formula- 60 tablets
Genestra TFE Female Formula- 60 tablets
Suggested Retail: $18.60
• Multivitamins, zinc, damiana, and glandular formulation
• An antioxidant for the maintenance of good health, helps to maintain eyesight, skin, membranes and immune function and helps in connective tissue formation (1)
• Convenient tablet format
• Increases patient compliance
TFE provides a combination of vitamins, zinc and damiana, along with ovary and uterus tissues. It is a factor in the maintenance of good health. Helps in the development and maintenance of bones and teeth and night vision. Helps to maintain eyesight, skin, membranes and immune function. Helps the body to metabolize carbohydrates, fats and proteins. Helps in connective tissue formation. An antioxidant for the maintenance of good health. Helps to prevent vitamin E and zinc deficiency (2).
1 NHPD Monograph on Multi-Vitamin and Mineral. October 2007.
2 NHPD Monograph on Multi-Vitamin and Mineral. October 2007.
Additional product info:
Over the last several decades, vitamin A has been used in the treatment of various skin disorders. An investigation was conducted to determine whether vitamin A (retinyl palmitate) supplementation at 25,000, 50,000, or 75,000 IU against a placebo significantly increases circulating RA concentrations of all-trans-, 9-cis-, and 13-cis-RA. The results of the study suggests that supplementation with retinyl palmitate is an effective means to increase circulating all-trans, 9-cis-, and 13-cis-RA concentrations among humans (3). Another study showed that retinol palmitate at 10,000 IU by mouth for 90 days significantly reduced rectal symptoms of radiation proctopathy, perhaps because of wound-healing effects (4).
Corneal haze and myopic regression are the main undesirable complications after excimer laser treatment. In the past few years, several authors indicated that keratocytes and epithelial cells are mainly involved in the healing response. In particular, it was suggested that the disappearance of anterior stromal keratocytes in response to excimer laser surgery was an initiating factor, which could lead to epithelial hyperplasia and eventually to haze formation and regression. Vitamin A exerts a moderate antioxidant activity and plays an essential part in epithelial growth and limbal stem cell differentiation, promoting corneal wound healing. As slower tissue regeneration causes an increased risk of accumulation of oxidant-inflicted damage in the tissue components, corneal re-epithelialisation time is crucial. A randomized, double masked clinical trial has been performed to evaluate the effect of a high dose vitamin A and E supplementation on corneal re-epithelialisation time, visual acuity and haze following photorefractive keratectomy (PRK). In this study, the results showed that vitamins A (25 000 IU retinol palmitate) and E (230 mg alpha-tocopherylnicotinate) for 3 months post PRK significantly decreased re-epithelialisation time, haze formation, and myopic regression occurrence (5).
Growing evidence suggest that antioxidant vitamins might reduce the risk of disease outcomes by their ability to scavenge free radicals. A case-control study with vitamin E (400 IU/d) and vitamin C (500 mg/d) supplementation in 40 patients for 2 months showed reduced lipid peroxidation and a strengthened antioxidant defense system. Hence, vitamin E and vitamin C supplementation may have beneficial effects on the heart by reducing oxidative stress (6). A group of researchers defined the dose-dependent effects of vitamin E (RRR-?-tocopherol) to suppress plasma concentrations of F2-isoprostanes, a biomarker of free radical mediated lipid peroxidation, in participants with polygenic hypercholesterolemia and enhanced oxidative stress, a population at risk for cardiovascular events. A time-course study was first performed in participants supplemented with 3200 IU/day of vitamin E for 20 weeks. A dose-ranging study was then performed in participants supplemented with 0, 100, 200, 400, 800, 1600, or 3200 IU/day of vitamin E for 16 weeks. In the time-course study, maximum suppression of plasma F2-Isoprostane concentrations did not occur until 16 weeks of supplementation. In the dose-ranging study there was a linear trend between the dosage of vitamin E and percent reduction in plasma F2-isoprostane concentrations which reached significance at doses of 1600 IU and 3200 IU (7).
A randomized, double-blind, placebo-controlled trial was conducted to determine the effect of 1 year of vitamin E supplementation on respiratory tract infections in elderly nursing home residents. A total of 617 persons aged at least 65 years and who met the study’s eligibility criteria were enrolled and Vitamin E (200 IU) or placebo capsule were administered daily. Fewer participants receiving vitamin E acquired 1 or more respiratory tract infections or upper respiratory tract infections. When common colds were analyzed in a post hoc subgroup analysis, the vitamin E group had a lower incidence of common cold and fewer participants in the vitamin E group acquired 1 or more colds. Supplementation with 200 IU per day of vitamin E did not have a statistically significant effect on lower respiratory tract infections in elderly nursing home residents. However, a protective effect of vitamin E supplementation on upper respiratory tract infections, particularly the common cold, was observed (8).
Adequate zinc status is critical for immune function. Zinc deficiency reduces generation of T cells, depresses humoral and cell-mediated immunity, leads to lymphopenia and thymic atrophy, and increases the frequency and number of infections (9). A prospective, randomized, controlled clinical trial was conducted involving 231 HIV-infected adults with low plasma zinc levels, who were randomly assigned to receive zinc (12 mg of elemental zinc for women and 15 mg for men) or placebo for 18 months. Zinc supplementation given to HIV-infected adults resulted in a 4-fold decrease in the likelihood of immunological failure, defined as a decrease of CD4+ cell count to
3 Sedjo RL, Ranger-Moore J, Foote J, Craft NE, Alberts DS, Xu MJ, Giuliano AR.Circulating endogenous retinoic acid concentrations among participants enrolled in a randomized placebo-controlled clinical trial of retinylpalmitate.Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1687-92.
4 Ehrenpreis ED, Jani A, Levitsky J, Ahn J, Hong J.A prospective, randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy.Dis Colon Rectum. 2005 Jan;48(1):1-8.
5 Vetrugno M, Maino A, Cardia G, Quaranta GM, Cardia L.A randomised, double masked, clinical trial of high dose vitamin A and vitamin E supplementation after photorefractive keratectomy.Br J Ophthalmol. 2001 May;85(5):537-9.
6 Karajibani M, Hashemi M, Montazerifar F, Dikshit M. Effect of vitamin E and C supplements on antioxidant defense system in cardiovascular disease patients in Zahedan, southeast Iran. J Nutr Sci Vitaminol (Tokyo). 2010;56(6):436-40.
7 Roberts LJ 2nd, Oates JA, Linton MF, Fazio S, Meador BP, Gross MD, Shyr Y, Morrow JD. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med. 2007 Nov 15;43(10):1388-93.
8 Meydani SN, Leka LS, Fine BC, Dallal GE, Keusch GT, Singh MF, Hamer DH. Vitamin E and respiratory tract infections in elderly nursing home residents: a randomized controlled trial. JAMA. 2004 Aug 18;292(7):828-36.
9 Baum MK, Lai S, Sales S, Page JB, Campa A. Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults. Clin Infect Dis. 2010 Jun 15;50(12):1653-60.
10 Baum MK, Lai S, Sales S, Page JB, Campa A. Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults. Clin Infect Dis. 2010 Jun 15;50(12):1653-60.
11 Mulder TP, van der Sluys Veer A, Verspaget HW, Griffioen G, Peña AS, Janssens AR, Lamers CB. Effect of oral zinc supplementation on metallothionein and superoxide dismutase concentrations in patients with inflammatory bowel disease. J Gastroenterol Hepatol. 1994 Sep-Oct;9(5):472-7.